SRR12696796
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- ADIPOGENESIS+0.400
- APOPTOSIS+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- DNA_REPAIR+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INFLAMMATORY_RESPONSE+0.400
- MYC_TARGETS_V1+0.400
- PROTEIN_SECRETION+0.400
Top 10 suppressed
- KRAS_SIGNALING_DN-0.300
- PANCREAS_BETA_CELLS-0.100
- SPERMATOGENESIS-0.100
- ALLOGRAFT_REJECTION+0.000
- APICAL_SURFACE+0.000
- BILE_ACID_METABOLISM+0.000
- ESTROGEN_RESPONSE_EARLY+0.000
- MYOGENESIS+0.000
- UV_RESPONSE_DN+0.000
- APICAL_JUNCTION+0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 61D1FD4D-F0FF-4D89-B26F-C1102685ED9D | — | — | 0.918 |
| 2 | EBE58DF8-7300-4D3E-9672-A4E7ADF46113 | — | — | 0.911 |
| 3 | 61496AD6-7265-4D58-87CC-4FEE9723106E | — | — | 0.908 |
| 4 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.903 |
| 5 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.903 |
| 6 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.901 |
| 7 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.900 |
| 8 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.900 |
| 9 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.899 |
| 10 | SRR934929 | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |